NeoGenomics announced the commercial availability of the RaDaR assay, a liquid biopsy test for molecular/minimal residual disease. MRD is the trace amounts of circulating tumor DNA that remain after surgery or other cancer treatment. The announcement comes after several recent publications demonstrating the clinical utility of the RaDaR test, particularly in the breast cancer space, with the CHiRP study published at ASCO 2022, and presentations of data for the TRACER and cTRAK-TN study cohorts at the most recent SABCS conference.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NEO:
